BHCM
TEVA icon

Brevan Howard Capital Management’s Teva Pharmaceuticals TEVA Stock Holding History

Brevan Howard Capital Management’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-200,000
Closed -$6.25M – 2487
2025
Q4 		$6.25M Sell
200,000
-109,300
-35% -$2.69M 0.07% 187
2025
Q3 		$6.25M Buy
+309,300
New +$5.43M 0.03% 203

Other funds holding TEVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $14.7B AUM 47% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $10.5B AUM 49.21% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $43.8B AUM 42.28% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brevan Howard Capital Management's TEVA Position: Q1 2026 in Review

Brevan Howard Capital Management sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 200,000 shares — an estimated $6.25M sold.

Brevan Howard Capital Management first reported a position in TEVA in Q3 2025 and held it in 2 quarters. The position peaked at $6.25M in Q4 2025. 650 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Brevan Howard Capital Management reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Brevan Howard Capital Management sold 200,000 Teva Pharmaceuticals shares in Q1 2026, an estimated $6.25M.
  • Brevan Howard Capital Management first reported a position in Teva Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Brevan Howard Capital Management's Teva Pharmaceuticals position peaked at $6.25M in Q4 2025.
  • 650 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Brevan Howard Capital Management's 13F filing for Q1 2026, filed 15 May 2026.